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Earlier studies investigated rural-urban colorectal cancer (CRC) screening disparities
among older adults or used surveys. The objective was to compare screening uptake
between rural and urban individuals 50–64 years of age using private health insurance.
Data were analyzed from 58,774 Blue Cross Blue Shield of Nebraska beneficiaries.
Logistic regression was used to assess the association between rural-urban and CRC
screening use. Results indicate that rural individuals were 56% more likely to use the
Fecal Occult Blood Test (FOBT) compared with urban residents, but rural females were
68% less likely to use FOBT. Individuals with few Primary Care Physician (PCP) visits
and rural-women are the least to receive screening. To enhance CRC screening, a
policy should be devised for the training and placement of female PCP in rural areas.
In particular, multilevel interventions, including education, more resources, and policies
to increase uptake of colorectal cancer screening, are needed. Further research is
warranted to investigate barriers to CRC screening in rural areas.
Keywords: healthcare disparities, screening, colorectal cancer, geography, private insurance

INTRODUCTION
Colorectal cancer (CRC) is ranked the third most common cancer in both women and men of the
United States (1, 2). The disease develops as a result of polyp development in the colon; though
benign initially, the tumor develops into a malignancy within 10 years (3–5). Past CRC research
suggests that screening reduces both the incidence and mortality rate by detecting polyps or tumors
at a precancerous stage (6, 7). For average-risk individuals who are age-eligible for screening (50–75
years old), the “United States Preventive Service Task Force (USPSTF)” recommends the following
screening tests: (1) annual high-sensitivity fecal occult blood test (FOBT); (2) sigmoidoscopy every
5 years with a fecal blood test every 3 years; or (3) colonoscopy every 10 years (8). Despite
the demonstrated effectiveness of these screening tests, CRC screening rates remain less than
expected. During 2015, only 62.6% of screen-eligible Americans received one of the recommended
screening tests, which is lower than the 80% target set by the “Centers for Disease Control and
Prevention’s” Colorectal Cancer Program (9). Americans 50–64 years old were among the least
screened individuals (10).
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Several factors predict CRC screening uptake. Factors
investigated are age, race, socioeconomic status (SES), availability
of insurance, screening cost, accessibility to a usual source of
care, communication with provider, level of awareness about
CRC screening, perceived colonoscopy pain, rural living, and
geographic access to screening facilities (11–16). Despite the
modest increase in CRC screening during the past years,
individuals who are 50–64 years old, live in rural areas with
low income, less education, and lack health insurance were
the groups with the lowest increase in CRC screening (9,
17, 18). For example, 71% of individuals aged ≥65 years
reported getting screened in 2015, but only 57% in the 50–64
year age group were screened (10, 19). Additionally, analysis
of the “Behavioral Risk Factor Surveillance System” (BRFSS)
showed that rural populations are unlikely to receive the
same level of CRC screening compared to urban populations.
Additional studies, including a study from Nebraska, had similar
findings (16, 17, 20, 21).
The evidence related to the association between living in
rural areas and CRC screening among the 50–64 years old,
privately insured population who lives in a rural state is not
clear. This unique rural, privately insured population under age
65 is assumed to have “financial access” to screening services.
Additionally, the private health insurance population consists
mainly of professional individuals who work full time, which is an
ideal population. Unlike an older population, busy professionals
are more likely to be sensitive to traveling (22, 23).
One-fifth of the U.S. population lives in rural locations, in
comparison with 35% rural residents in Nebraska (24, 25). CRC
screening in Nebraska has been below the national average. The
state ranks 37th nationally in CRC screening, with only 65% of
individuals 50–57 years old screened (9). While the screening rate
for Nebraskans aged ≥65 years was 72%, the screening rate for
individuals between 50–64 years was only 60% (26). In addition
to the differences due to age (27, 28), geographic location is a
determinant factor for CRC screening. Compared with the urban
population, the rural population was 60% less likely to undergo
any CRC screening and 57% less likely to undergo colonoscopy
screening than their urban counterpart (16). In addition, the
use of preventive services and Primary Care Physician (PCP)
(PCPs are general practitioners, internists, obstetric gynecologist,
and family practitioner) visits are lower in a rural population
(27, 29, 30). Combined, individuals who are 50–64 years old and
rural residents are the least populations to have CRC screening.
Previous research was based on self-report surveys (e.g.,
NHIS) or older adults (e.g., Medicare beneficiaries). The current
study was designed to evaluate CRC screening uptake among
a privately insured population in a rural state. We hypothesize
that FOBT use is higher and colonoscopy use lower in rural
population compared to the urban population after adjusting for
covariates. In addition, we hypothesize that the urban population
would have a higher number of PCP visits, and individuals
with more PCP visits would be more likely to receive CRC

screening. We also investigated the annual use of the FOBT-test
by rural-urban status. Elucidating rural-urban disparities would
assist policymakers in increasing the rates of colorectal cancer
screening among rural residents.

MATERIALS AND METHODS
Data Sources
The data source has been described previously (31). A
retrospective cohort study was conducted using data from the
Blue Cross Blue Shield of Nebraska (BCBSNE). Blue Cross Blue
Shield of Nebraska is a large private health insurer covering
more than 700,000 individuals in the state of Nebraska (32).
Data consists of claims from inpatient, professional services, and
outpatient facilities and comprise codes for disease diagnosis and
procedures, of the service date, and the ZIP code of the provider.
Members’ demographic variables such as age, gender, and ZIP
code were all retrieved. The beginning and end dates of coverage
were also captured by BCBSNE.

Study Population
Participants were beneficiaries of BCBSNE who were
continuously enrolled in the plan from January 1st, 2013 to
December 30th, 2015, 50–64 years old, and not diagnosed with
CRC, polyps, or inflammatory bowel diseases. We excluded
beneficiaries older than 65 because the data possibly may not
contain claims for all of their Medicare-covered health services.
We also excluded members with CRC, polyps, or inflammatory
bowel diseases (i.e., high-risk groups) because we wanted to focus
on members who are more likely to receive a CRC screening
and not a work-up for an existing disease (i.e., screen-eligible
population) (33). Figure 1 shows the eligibility conditions and
the number of patients excluded for each condition. The detailed
International Classification of Diseases, 9th Revision, Clinical
Modification (ICD-9-CM), and 10th Revision (ICD-10-CM)
diagnosis codes are shown in Supplementary Figure 1.

Study Variables
Patient Characteristics
The enrollment file was used to extract the beginning and
ending dates of coverage and services. The demographics of
patients, such as age, gender, and the ZIP code of residence,
were derived from the member file. Clinical and test use variables
such as FOBT use, colonoscopy use, PCP visits, and the Charlson
Comorbidity Index (CCI) were extracted from the claim file
using the international classification of disease fields and current
procedural terminology (CPT) fields from the claims file.
A PCP visit was defined as an outpatient visit with any of
the following types of providers: general practitioner, internist,
obstetric gynecologist, and family practitioner. Patients who had
at least one outpatient claim associated with a PCP in the calendar
years of 2013 or 2014 was considered to have had a PCP visit. The
PCP visit was categorized into no visits vs. any visits and 0, 1–2,
3–5, and ≥6 visits.
The CCI was calculated to determine the burden of disease
among the study population. To apply the index to administrative
data, many authors modified the comorbidity index and

Abbreviations: CRC, Colorectal Cancer; BCBSNE, Blue Cross Blue Shield of
Nebraska; RUCA, Rural Urban Commuting Area; ICD, International Classification
of Diseases; FOBT, Fecal Occult Blood Test.
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FIGURE 1 | Eligibility criteria for the study population.

validated its use with administrative data. For instance, Quan
modifications were used in this study by adjusting the weights of
comorbidities (34). Charlson Comorbidity Index was computed
during the years 2013 and 2014 and was categorized into 0, 1,
and ≥2.

of 2,500–9,999 individuals) and “rural commuting areas” (i.e.,
primary flow to a tract outside a U.A. or U.C.) with numbers
between 1 and 10. The numbers are segmented into 21 secondary
codes depending on commuting flows.
Though the original RUCA classification was based on the
census tract, it uses the ZIP code as its geographic unit. The
updated RUCA codes are dependent on the 2010 decennial
census and the 2006–2010 “American Community Survey.” In
the current study, the 33 codes were combined into urban and
rural as recommended by the “Washington, Montana, Wyoming,
Idaho, and Alaska Rural Health Research Center” (35, 36).

Rural-Urban Measurement
“Rural-Urban Community Area Codes” (RUCA) was used
to determine members’ rural-urban status (35). Rural-Urban
Community Area Codes is constructed from census tract and
uses the standard “Bureau of Census Urbanized Area” (U.A.)
and “Urban Cluster” (U.C.) definition in combination with
work commuting information to characterize all of the Nation’s
census tracts regarding their rural and urban status and their
relationship. The classification designates “metropolitan” (i.e.,
primary commuting flow within a U.A.), “micropolitan” (i.e.,
large rural or primary flow within an U.C. of 10,000–49,999
individuals), “small town” (i.e., primary flow within an U.C.
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rates between urban and rural members, we used Chi-squaretests. The same test was used to assess the CRC screening use
across years. All tests were 2-tailed, and the chosen α level was
0.05. SAS statistical software version 9.4 (SAS Institute Inc. Cary,
NC) was used to perform all analyses. This study was approved by
the University of Nebraska Medical Center Institutional Review
Board (IRB# 366-1).

TABLE 1 | Characteristics of BCBSNE members eligible for colorectal cancer
screening by rural/urban residence (N = 58,774).
Characteristics

Rural
(n = 30,460)

Urban
(n = 28,312)

P-value

<0.001

Age
50–54

9,132 (30.0)

9,381 (33.0)

55–59

10,959 (36.0)

9,988 (35.0)

60–64

10,369 (34.0)

8,943 (32.0)

Female

16,052 (53.0)

15,477 (55.0)

Male

14,408 (47.0)

12,835 (45.0)

Yes

23,122 (76.0)

22,551 (80.0)

No

7,338 (24.0)

5,761 (20.0)

0

20,948 (69.0)

18,646 (66.0)

1

5,657 (18.0)

5,577 (20.0)

≥2

3,855 (13.0)

4,089 (14.0)

RESULTS

Gender
<0.001

Applying the eligibility condition resulted in a total cohort of
58,774 (Figure 1). Table 1 shows the characteristics of individuals
who are eligible for CRC screening by rural and urban status. It
also presents the eligible population by age, gender, PCP visits,
and CCI in 2013 and 2014. Most of the urban population is female
(55%), and the majority of the urban population has visited the
PCP during 2013–2014 (80%).
Figure 2 and Supplementary Figure 2 shows the overall
annual FOBT use among the rural and urban populations.
Between 2012 and 2016, FOBT use was significantly higher in
rural residents compared to urban populations. The findings
suggest that rural members had a higher proportion of FOBT
use compared to urban members (P < 0.05). Rural members
had a consistently higher FOBT use for age groups 50–54 and
55–59, but this pattern was reversed for the oldest age group of
60–64 years during the year 2016. In rural areas, females had
consistently higher use of FOBT than males (e.g., 15% of females
used FOBT, while only 7% of males used FOBT during 2012).
For both areas, the frequency of PCP visits was proportionally
associated with FOBT use.
Table 2 displays predictors of FOBT use in 2015. After
controlling for age, gender, CCI, and PCP visits, rural residents
had 56% increased odds of receiving FOBT compared to urban
populations (OR = 1.56; 95% CI: 1.45, 1.69). Females had 85%
increased odds of FOBT use compared to males (OR = 1.85; 95%
CI: 1.69, 2.0). For PCP visits, the higher the number of visits, the
higher the odds of FOBT use. Overall, the use of FOBT in the
past year was 4.2%. We also found an interaction between ruralurban status and gender (Table 3). While rural females had 68%
decreased odds of using FOBT during 2015 (OR = 0.32; 95% CI:
0.28, 0.36), urban females had 15% larger odds of using FOBT
(OR = 1.15; 95% CI: 1.01, 1.31).
The predictors for colonoscopy use in 2015 are shown
in Table 4. Although the univariate analysis showed higher
colonoscopy use among urban residents (OR = 1.09; 95%
CI: 1.01, 1.17), the multivariate analysis showed no significant
difference (OR = 1.06; 95% CI: 0.98, 1.14). There is an inverse
association between age and the colonoscopy use during 2015.
While individuals older than 60 years old had a 14% decreased
in odds of colonoscopy use (OR = 0.86; 95% CI: 0.80, 0.93)
compared with those <55 years old, individuals between 55–
59 years had 44% decreased odds (OR = 56; 95% CI: 0.60,
0.71). Compared with males, females had 16% increased odds
in FOBT use (OR = 1.16; 95% CI: 1.09, 1.25). In addition,
the higher the frequency of PCP visits, the higher the odds of
colonoscopy use.

PCPs visits (2013–2014)
<0.001

CCI (2013–2014)
<0.001

FOBT during the year. The CPT codes used to identify FOBT
uptake were: 82,270, 82,272, and 82,274 (37).
Colonoscopy was defined as the proportion of the study
population who have ≥1 claim for a colonoscopy during the
year. The following CPT and ICD codes were used to identify
colonoscopy uptake: 44,388–44,394, 44,397, 45,355, 45,379,
45,381, 45,386, 45,387, 45,378, 45,380, 45,382–45,385, 45.21–
45.23, and 45.25 (37). Because administrative data do not provide
information about the indication of colonoscopy (i.e., screening,
diagnostic, or surveillance), we were unable to identify the
purpose of the test (33, 38, 39). However, to limit the population
to members who potentially used screening-colonoscopy, we
restricted the sample to those with the following procedural codes
that indicate screening: V7651, Z1211, V7641, and Z1212 (40).

Data Analysis
Age, gender, rural-urban status, number of PCP visits during
2013 and 2014, and the CCI level during 2013 and 2014 were
compared between test users (FOBT or colonoscopy) vs. nonusers using the Chi-square-test. In the univariate analysis, we
compared the FOBT use in 2015 vs. no FOBT use and the
colonoscopy use in 2015 vs. no colonoscopy use using logistic
regression. To assess the predictor’s significance, Wald-tests
were used. We reported OR of FOBT screening and the 95%
confidence intervals (CI) and OR of colonoscopy screening and
the 95% CI. We also fitted two multivariate logistic regression
models for FOBT and colonoscopy to evaluate the relationship
between rural-urban status and screening use adjusted for age,
gender, PCP visits, and CCI.
To estimate the annual prevalence rate for FOBT (years 2012–
2016), the numerator was computed as the number of members
with at least one paid claim for the specified screening test during
the specific year. The denominator was the frequency of members
eligible for screening during the specific year. To compare the
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FIGURE 2 | Annual fecal occult blood test in Blue Cross Blue Shield Nebraska population, 2012–2016.

TABLE 2 | Univariate and multivariate analyses of variables associated with FOBT screening using logistic regression models, BCBSNE 2013–2015.
FOBT use in 2015
FOBT use

No FOBT use

P-value

Univariate OR (95% CI)

Multivariate OR (95% CI)

50–54

729 (29.0)

17,785 (32.0)

0.03

1.0

1.0

55–59

891 (36.0)

20,056 (36.0)

1.08 (0.98, 1.20)

1.05 (0.95, 1.17)

60–64

863 (35.0)

18,450 (33.0)

1.14 (1.03, 1.26)

1.08 (0.97, 1.19)

Age

Gender
Male

803 (32)

26,441 (47.0)

1,680 (68)

29,850 (53.0)

Urban

952 (38.0)

27,334 (49.0)

Rural

1,531 (62.0)

28,955 (51.0)

Female

<0.0001

1.0

1.0

1.85 (1.69, 2.04)

1.85 (1.69, 2.0)

Member status
<0.0001

1.0

1.0

1.51 (1.41, 1.67)

1.56 (1.45, 1.69)

PCP visits in 2013–2014
0

396 (16.0)

12,703 (23.0)

1–2

646 (26.0)

15,062 (27.0)

3–5

733 (30.0)

14,796 (26.0)

1.59 (1.40, 1.80)

1.59 (1.40, 1.80)

6–9

457 (18.0)

8,490 (15.0)

1.73 (1.50, 1.98)

1.71 (1.49, 1.96)

≥10

251 (10.0)

5,240 (9.0)

1.54 (1.31, 1.81)

1.49 (1.26, 1.75)

0

1,929 (78.0)

43,847 (78.0)

1.0

1.0

1

373 (15.0)

7,299 (15.0)

1.02 (0.91, 1.14)

0.99 (0.87, 1.11)

≥2

181 (7.0)

4,145 (7.0)

0.99 (0.85, 1.16)

0.95 (0.81, 1.11)

<0.0001

1.0

1.0

1.38 (1.21, 1.56)

1.37 (1.21, 1.56)

CCI in 2013–2014
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DISCUSSION

significant difference in colonoscopy use between rural and urban
residents. It also showed an interaction between rural-urban
status and gender and the use of FOBT. Thirdly, multivariate
regression analysis also indicated that the odds of FOBT and
colonoscopy uses were higher among females and were positively
associated with PCP visits, but colonoscopy use was lower among
individuals older than 55 and those with ≥2 CCI.
Overall, we found a decline in FOBT use since 2013; similar
findings were reported previously (42–44). While the annual
FOBT use was 10–11% is slightly higher than recent rates from
national surveys, which was between 5–8% (17, 37, 45), it is
comparable to claims-based studies (46). For instance, Ladabaum
and colleagues used a sample of 21 million privately insured
population and found that ∼10% used the annual FOBT-test
during 2009 (46). The discrepancy between our findings and
results from surveys is possible because their results are based
on self-reported data, prone to recall bias, and some of the
population surveyed is uninsured or underinsured, which might
result in lower screening rates (47, 48). Among the continuously
enrolled individuals from 2013 to 2015, we found that 5% of
the rural population used FOBT during 2015, similar to findings
from a Nebraskan rural study (18).
Furthermore, we found that the rural population is 56%
more likely to use FOBT compared with the urban population,
similar to a previous study using national data (17), but not to
a study using data from Texas (20). The finding is encouraging
since it suggests that this privately insured rural population
has access to non-invasive screening tests through their PCPs,
a test that is linked with a reduction in both the incidence

The current study hypothesized that FOBT use is higher, and
colonoscopy use is lower in the rural population and that the
urban population would have a higher frequency of PCP visits,
and individuals with higher PCP visits will be more likely
to receive CRC screening. The functions of PCP consist of
discussion and suggestions about screening, performing noninvasive screening tests (e.g., FOBT), and referring patients
to specialists (e.g., gastroenterologists) who can perform an
endoscopic screening test (41). Our study uncovered several
significant findings of the differences in the use of CRC screening
between the rural and the urban privately insured populations.
Firstly, FOBT utilization was significantly decreasing since 2013,
among both rural and urban populations (P < 0.05). Secondly,
multivariate regression analysis indicated that though FOBT use
was significantly higher in the rural population, there was no

TABLE 3 | Adjusted association between rural-urban status and FOBT use.
Rural-urban status

Gender
Male

Female

Rural

1.0

0.32 (0.28, 0.36)

Urban

1.0

1.15 (1.01, 1.31)

Adjusted for age, gender, Primary Care Physician visits (PCP), and Charlson Comorbidity
Index (CCI).

TABLE 4 | Univariate and multivariate analyses of variables associated with the use of colonoscopy using logistic regression models, BCBSNE 2013–2015.
Colonoscopy use in 2015
Colonoscopy use

No colonoscopy use

P

Univariate OR (95% CI)

Multivariate OR (95% CI)

50–54

1,308 (43.0)

17,206 (31.0)

<0.0001

1.0

1.0

55–59

809 (27.0)

20,138 (36.0)

0.53 (0.48, 0.58)

0.56 (0.60, 0.71)

60–64

926 (30.0)

18,387 (33.0)

0.66 (0.61, 0.72)

0.86 (0.80, 0.93)

Male

1,297 (43.0)

25,947 (47.0)

Female

1,746 (57.0)

29,784 (53.0)

<0.0001
0.02

Age

Gender
1.0

1.0

1.18 (1.09, 1.26)

1.16 (1.09, 1.25)

Member status
Rural

1,515 (50.0)

28,971 (52.0)

Urban

1,528 (50.2)

26,758 (48.0)

1.0

1.0

1.09 (1.01, 1.17)

1.06 (0.98, 1.14)

PCP visits in 2013–2014
0

521 (17.0)

12,578 (23.0)

1.0

1.0

1–2

834 (27.0)

14,874 (27.0)

1.35 (1.21, 1.51)

1.36 (1.21, 1.52)

<0.0001

3–5

895 (29.0)

14,634 (26.0)

1.48 (1.32, 1.65)

1.51 (1.35, 1.68)

≥6

793 (26.0)

13,645 (24.0)

1.40 (1.25, 1.57)

1.47 (1.31, 1.65)

0

2,415 (79.0)

43,361 (78.0)

1.0

1.0

1

439 (14.0)

8,233 (15.0)

0.95 (0.86, 1.06)

0.95 (0.85, 1.05)

≥2

189 (6.0)

4,137 (7.0)

0.82 (0.70, 0.95)

0.84 (0.71, 0.97)

CCI in 2013–2014
0.03

PCP visits, Primary Care Physician visits; CCI, Charlson Comorbidity Index.
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are less likely to use FOBT compared to rural males. It is possible
that PCPs in rural areas are less likely to offer females alternative
testing when colonoscopy is not possible (50). Alternatively,
rural females are at a disadvantage for FOBT uptakes since
85.8% of rural Nebraskans’ PCPs are male, and that patients
who live in rural Nebraska and saw a male PCPs are 44% less
likely to be up to date in CRC screening compared to those
who saw a female PCPs (18). Consequently, policies advocating
for an increased number of female PCPs in rural areas should
be prioritized.
The current study has many strengths. Our cohort consisted of
a large sample derived from the largest private health insurer in
Nebraska, which has never been studied. Additionally, the private
health insurance population consists mainly of professional
individuals who work full time, an ideal population because,
unlike an older population, busy professionals are more likely to
be sensitive to traveling or taking off time to undergo screening.
Also, the current result reflects a CRC screening test utilization in
the community setting.
The findings should be interpreted with caution. First, about
2% of BCBSNE members ended their membership during
December 2014, and this may have slightly impacted the total
number of members eligible for CRC screening during the
year 2015. Second, we were uncertain about the intent of
the colonoscopy-test because it was derived from claim data;
nonetheless, we restricted colonoscopy users to individuals with
claims indicating screening as previously reported (37, 40).
Third, we were limited to 4 years of data, and therefore we
were unable to assess the colonoscopy use during the 10-year
recommended period for screening colonoscopy suggested by
the USPSTF. Extrapolating our colonoscopy use during 2015
to 10-year utilization would result in colonoscopy utilization
of 51.8%, an estimate similar to what has been reported
during 2015 among 50–64 years old privately insured using
national data; 50–62% (45) and to a study from Nebraska,
53% (18). It also resembles findings from national surveys
such as NHIS (53–56%) and BRFSS (53.8%) (Table 5). Fourth,
the current study is constrained to people who are privately
insured and live in Nebraska, and our results are therefore not
generalizable to other states, with different types of insurance,
the underinsured or the uninsured. Nevertheless, the population
of Nebraska represents the population of the U.S. well in their
sociodemographic characteristics, with the only difference that
Nebraska has a higher percentage of whites than the U.S. average
(79.0 vs. 60.7%) (68). Fifth, prior studies show that SES is
positively associated with access to health services use (69).
In our study, we were unable to adjust for the effect of SES.
However, our sample consists of a privately-insured population
who we believe is homogenous. We also believe that insurance
status as a proxy to SES since it has been found important
in predicting health outcomes in terms of access to health
care (69).
We found that the overall rural population was significantly
more likely to use FOBT, but females who live in rural areas
are less likely to receive FOBT compared to rural males. This
disparity might reflect the characteristics of PCPs practicing in
rural areas who are pre-dominantly male and are less likely

and mortality due to CRC (49). Conversely, it might reflect
a shortage of specialists to perform a colonoscopy in rural
areas, prompting local PCPs to recommend non-invasive tests
(50). If that is the case, training non-specialists to perform
colonoscopy is necessary for both screening and follow-up
of FOBT-positive individuals. Surprisingly, while the urban
population in the current study was significantly more likely to
visit PCPs during 2013–2014, rural residents were more likely to
use FOBT.
We observed that the rural population was 56% more likely
than the urban population to use FOBT, but rural women
were 68% less likely than rural men to use FOBT. The result
suggests gender disparity in FOBT use. A potential contribution
to the disparity in FOBT use is the current characteristic
of practicing PCPs in rural Nebraska, pre-dominantly males
(85%). Prior literature shows that male PCPs are less likely
than female PCPs to practice patient-centered communication
or spend more time with the patient during clinic visits to
discuss preventive services such as screening (51, 52). Possible
targeted interventions that could ameliorate gender disparity in
FOBT use among rural women in Nebraska and other similar
rural populations would include increasing the supply of female
PCPs in rural areas or enhancing male PCPs’ awareness about
CRC screening that could consist of the implementation of
reminder systems.
The univariate analysis shows that urban residents were more
likely to use colonoscopy, though the association disappeared
in the multivariate model. The non-significant finding has been
reported previously using a national sample (20) and confirmed
in this privately insured population. This finding is surprising
given that all individuals in this study are privately insured, and
that the higher rates of uninsured or underinsured in rural areas
reported previously in the national survey have no impact on the
association between rural-urban status and CRC-test use among
our population. In particular, the comprehensive health care
reform law that was enacted in March 2010 makes compulsory
that private health insurance plans to cover all preventive services
suggested by the “United States Preventive Services Task Force”
and graded “A” or “B,” which cover CRC screening, with no outof-pocket costs for members (53). Accordingly, barriers other
than health access, which was equal between the rural and urban
residents, should be illuminated in future studies, especially
factors related to the increased distance to providers or decreased
number of specialists in rural areas (54).
Congruent with prior research (33, 55–59), we found that
the more frequent the PCP visits, the more likely screening
tests will be used. The associations between PCP visits and
test receipts remained significant after adjustment for CCI. The
result indicates that the discussion between PCP and patients
about preventive services such as screening occurs during annual
checkups or routine care visits vs. acute visits (60–62). Therefore,
not only access to care has an important role in determining
whether individuals receive CRC screening test but also the
frequency of PCP visits. Lastly, there was an interaction between
gender and rural-urban status and the use of FOBT. Urban
females were significantly more likely to receive FOBT compared
to urban males (50, 63). However, it is unclear why rural females
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TABLE 5 | Comparison of CRC screening with national and state data (%).
Annual FOBT

Annual colonoscopy

Current study

10

14

5

51.8

-

NHIS (6, 19, 45, 64)

10

-

5.9

53–56

56–61

BRFSS (17, 20, 36, 65)
Other claims data (37, 43, 45, 46, 66, 67)
EMRs in Nebraska (18)

FOBT during past year

Colonoscopy during past 10 years

Up to date

9

26–32

-

53.8

54–65

7.9–10.4

10–20.9

-

53

47.4–63.4

-

-

5

53

55

EMRs, Electronic medical records; NHIS, National Health Interview Survey; BRFSS, Behavior Risk Factor Surveillance System.

to recommend screening (18). The value of preparing and
placement of female PCPs in rural areas must be a priority
since it could contribute to an increase in CRC screening.
In particular, providers should be encouraged to discuss CRC
screening during patients’ regular visits when the use of
preventive services in general, and CRC screening, especially,
are detailed.

study in accordance with the national legislation and the
institutional requirements.

AUTHOR CONTRIBUTIONS
MA planned the study, conducted the analyses, and drafted
the manuscript. MA, AS, KI, and SW-G helped with the study
planning and aided with the manuscript preparation. JM assisted
with revising data analysis. SW-G and AS helped with data
acquisition. All authors helped with manuscript revisions, read,
and approved the submitted manuscript.

DATA AVAILABILITY STATEMENT
Data cannot be shared publicly because of sensitive identifier that
have been used in this study, which were used under license for
the current study. Moreover, we have signed a contract with the
BCBSNE in which we have stated that all data are reserved. Data
are available for any interested researcher who meets the criteria
for access to confidential data from: www.nebraskablue.com.

ACKNOWLEDGMENTS
The authors acknowledge the Blue Cross and Blue Shield of
Nebraska for providing the data.

ETHICS STATEMENT

SUPPLEMENTARY MATERIAL

The University of Nebraska Medical Center Institutional
Review Board (IRB# 366-1) approved this study. Written
informed consent for participation was not required for this

The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fpubh.
2020.532950/full#supplementary-material

REFERENCES

8. Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling
JW, García FA, et al. Screening for colorectal cancer: U.S. Preventive
Services Task Force recommendation statement. JAMA. (2016) 315:2564–75.
doi: 10.1001/jama.2016.5989
9. Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RG, Barzi A, et al.
Colorectal cancer statistics, 2017. CA Cancer J Clin. (2017) 67:177–93.
doi: 10.3322/caac.21395
10. Hall IJ, Tangka FK, Sabatino SA, Thompson TD, Graubard BI, Breen N.
Patterns and trends in cancer screening in the United States. Prev Chronic
Dis. (2018) 15:E97. doi: 10.5888/pcd15.170465
11. Beydoun HA, Beydoun MA. Predictors of colorectal cancer screening
behaviors among average-risk older adults in the United States. Cancer Causes
Control. (2008) 19:339–59. doi: 10.1007/s10552-007-9100-y
12. Garcia-Dominic O, Lengerich EJ, Wray LA, Parrott R, Aumiller B,
Kluhsman B, et al. Barriers to CRC screening among Latino adults
in Pennsylvania: ACCN results. Am J Health Behav. (2012) 36:153–67.
doi: 10.5993/AJHB.36.2.2
13. Khatami S, Xuan L, Roman R, Zhang S, McConnel C, Halm EA, et al. Modestly
increased use of colonoscopy when copayments are waived. Clin Gastroenterol
Hepatol. (2012) 10:761–6.e1. doi: 10.1016/j.cgh.2012.02.027
14. McLachlan SA, Clements A, Austoker J. Patients’ experiences and
reported barriers to colonoscopy in the screening context–a systematic
review of the literature. Patient Educ Couns. (2012) 86:137–46.
doi: 10.1016/j.pec.2011.04.010

1. Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J
Clin. (2014) 64:104–17. doi: 10.3322/caac.21220
2. Kohler BA, Sherman RL, Howlader N, Jemal A, Ryerson AB, Henry KA, et al.
Annual report to the nation on the status of cancer, 1975–2011, featuring
incidence of breast cancer subtypes by race/ethnicity, poverty, and state. J Natl
Cancer Inst. (2015) 107:djv048. doi: 10.1093/jnci/djv048
3. Pickhardt PJ, Kim DH, Pooler BD, Hinshaw JL, Barlow D, Jensen D, et al.
Assessment of volumetric growth rates of small colorectal polyps with C.T.
colonography: a longitudinal study of natural history. Lancet Oncol. (2013)
14:711–20. doi: 10.1016/S1470-2045(13)70216-X
4. Meester RG, Doubeni CA, Zauber AG, Goede SL, Levin TR, Corley DA,
et al. Public health impact of achieving 80% colorectal cancer screening rates
in the United States by 2018. Cancer. (2015) 121:2281-5. doi: 10.1002/cncr.
29336
5. Risio M. The natural history of colorectal adenomas and early cancer. Der
Pathologe. (2012) 33:206–10. doi: 10.1007/s00292-012-1640-6
6. Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC,
et al. Colorectal cancer statistics, 2020. CA Cancer J Clin. (2020) 70:145–64.
doi: 10.3322/caac.21601
7. Potter MB. Strategies and resources to address colorectal cancer screening
rates and disparities in the United States and globally. Ann Rev Public Health.
(2013) 34:413–29. doi: 10.1146/annurev-publhealth-031912-114436

Frontiers in Public Health | www.frontiersin.org

8

November 2020 | Volume 8 | Article 532950

Alyabsi et al.

Colorectal Cancer Screening

36. Anderson AE, Henry KA, Samadder NJ, Merrill RM, Kinney AY. Rural vs.
urban residence affects risk-appropriate colorectal cancer screening. Clin
Gastroenterol Hepatol. (2013) 11:526–33. doi: 10.1016/j.cgh.2012.11.025
37. Schenck AP, Peacock SC, Klabunde CN, Lapin P, Coan JF, Brown ML. Trends
in colorectal cancer test use in the medicare population, 1998–2005. Am J Prev
Med. (2009) 37:1–7. doi: 10.1016/j.amepre.2009.03.009
38. Pollack LA, Blackman DK, Wilson KM, Seeff LC, Nadel MR. Colorectal cancer
test use among Hispanic and non-Hispanic U.S. populations. Prev Chronic
Dis. (2006) 3:A50.
39. Klabunde C, Joseph D, King J, White A, Plescia M. Vital signs: colorectal
cancer screening test use—United States, 2012. MMWR Morb Mortal Wkly
Rep. (2013) 62:881–8.
40. Ko CW, Dominitz JA, Neradilek M, Polissar N, Green P, Kreuter W, et al.
Determination of colonoscopy indication from administrative claims data.
Med Care. (2014) 52:e21–9. doi: 10.1097/MLR.0b013e31824ebdf5
41. Levin B, Lieberman DA, McFarland B, Smith RA, Brooks D, Andrews
KS, et al. Screening and surveillance for the early detection of colorectal
cancer and adenomatous polyps, 2008: a joint guideline from the American
Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and
the American College of Radiology. CA Cancer J Clin. (2008) 58:130–60.
doi: 10.3322/CA.2007.0018
42. Meissner HI, Breen N, Klabunde CN, Vernon SW. Patterns of
colorectal cancer screening uptake among men and women in the
United States. Cancer Epidemiol Biomarkers Prev. (2006) 15:389–94.
doi: 10.1158/1055-9965.EPI-05-0678
43. Fenton JJ, Cai Y, Green P, Beckett LA, Franks P, Baldwin LM. Trends in
colorectal cancer testing among medicare subpopulations. Am J Prev Med.
(2008) 35:194–202. doi: 10.1016/j.amepre.2008.05.029
44. Hao Y, Jemal A, Zhang X, Ward EM. Trends in colorectal cancer
incidence rates by age, race/ethnicity, and indices of access to medical
care, 1995–2004 (United States). Cancer Causes Control. (2009) 20:1855–63.
doi: 10.1007/s10552-009-9379-y
45. de Moor JS, Cohen RA, Shapiro JA, Nadel MR, Sabatino SA, Robin Yabroff
K, et al. Colorectal cancer screening in the United States: trends from 2008 to
2015 and variation by health insurance coverage. Prev Med. (2018) 112:199–
206. doi: 10.1016/j.ypmed.2018.05.001
46. Ladabaum U, Levin Z, Mannalithara A, Brill JV, Bundorf MK. Colorectal
testing utilization and payments in a large cohort of commercially insured U.S.
adults. Am J Gastroenterol. (2014) 109:1513–25. doi: 10.1038/ajg.2014.64
47. Dodou D, de Winter JC. Agreement between self-reported and registered
colorectal cancer screening: a meta-analysis. Eur J Cancer Care (Engl). (2015)
24:286–98. doi: 10.1111/ecc.12204
48. Bradbury BD, Brooks DR, Brawarsky P, Mucci LA. Test-retest reliability
of colorectal testing questions on the Massachusetts Behavioral Risk
Factor Surveillance System (BRFSS). Prev Med. (2005) 41:303–11.
doi: 10.1016/j.ypmed.2004.11.015
49. Allison JE. The effect of fecal occult-blood screening on the incidence of
colorectal cancer. N Engl J Med. (2001) 344:1022; author reply 3.
50. Rosenwasser LA, McCall-Hosenfeld JS, Weisman CS, Hillemeier MM, Perry
AN, Chuang CH. Barriers to colorectal cancer screening among women in
rural central Pennsylvania: primary care physicians’ perspective. Rural Remote
Health. (2013) 13:2504. doi: 10.1056/NEJM200011303432203
51. Flocke SA, Gilchrist V. Physician and patient gender concordance and the
delivery of comprehensive clinical preventive services. Med Care. (2005)
43:486–92. doi: 10.1097/01.mlr.0000160418.72625.1c
52. Roter DL, Hall JA, Aoki Y. Physician gender effects in medical
communication: a meta-analytic review. JAMA. (2002) 288:756–64.
doi: 10.1001/jama.288.6.756
53. Pollitz K, Lucia K, Keith K, Smith R, Doroshenk M, Wolf H, et al.
Coverage of Colonoscopies Under the Affordable Care Act’s Prevention Benefit.
(2012). Available online at: http://files.kff.org/attachment/report-coverageof-colonoscopies-under-the-affordable-care (accessed November 1, 2017).
54. Massarweh NN, Chiang YJ, Xing Y, Chang GJ, Haynes AB, You YN,
et al. Association between travel distance and metastatic disease at
diagnosis among patients with colon cancer. J Clin Oncol. (2014) 32:942–8.
doi: 10.1200/JCO.2013.52.3845
55. Cardarelli R, Thomas JE. Having a personal health care provider and receipt of
colorectal cancer testing. Ann Fam Med. (2009) 7:5–10. doi: 10.1370/afm.904

15. Guessous I, Dash C, Lapin P, Doroshenk M, Smith RA, Klabunde CN, et al.
Colorectal cancer screening barriers and facilitators in older persons. Prev
Med. (2010) 50:3–10. doi: 10.1016/j.ypmed.2009.12.005
16. Hughes AG, Watanabe-Galloway S, Schnell P, Soliman AS. Rural-urban
differences in colorectal cancer screening barriers in Nebraska. J Commun
Health. (2015) 40:1065–74. doi: 10.1007/s10900-015-0032-2
17. Cole AM, Jackson JE, Doescher M. Urban-rural disparities in colorectal cancer
screening: cross-sectional analysis of 1998–2005 data from the Centers for
Disease Control’s Behavioral Risk Factor Surveillance Study. Cancer Med.
(2012) 1:350–6. doi: 10.1002/cam4.40
18. Wang H, Qiu F, Gregg A, Chen B, Kim J, Young L, et al. Barriers and
facilitators of colorectal cancer screening for patients of rural accountable care
organization clinics: a multilevel analysis. J Rural Health. (2018) 34:202–12.
doi: 10.1111/jrh.12248
19. White A, Thompson TD, White MC, Sabatino SA, de Moor J, DoriaRose PV, et al. Cancer screening test use—United States, 2015. MMWR
Morb Mortal Wkly Rep. (2017) 66:201–6. doi: 10.15585/mmwr.mm
6608a1
20. Ojinnaka CO, Choi Y, Kum HC, Bolin JN. Predictors of colorectal cancer
screening: does rurality play a role? J Rural Health. (2015) 31:254–68.
doi: 10.1111/jrh.12104
21. Bennett KJ, Probst JC, Bellinger JD. Receipt of cancer screening services:
surprising results for some rural minorities. J Rural Health. (2012) 28:63–72.
doi: 10.1111/j.1748-0361.2011.00365.x
22. Denberg TD, Melhado TV, Coombes JM, Beaty BL, Berman K, Byers TE,
et al. Predictors of nonadherence to screening colonoscopy. J Gen Intern Med.
(2005) 20:989–95. doi: 10.1111/j.1525-1497.2005.00164.x
23. Subramanian S, Klosterman M, Amonkar MM, Hunt TL. Adherence with
colorectal cancer screening guidelines: a review. Prev Med. (2004) 38:536–50.
doi: 10.1016/j.ypmed.2003.12.011
24. U.S. Census Bureau. Annual Estimates of the Resident Population: April 1, 2010
to July 1st, 2014. (2014). Available online at: https://factfinder.census.gov/
faces/tableservices/jsf/pages/productview.xhtml?src=CF (accessed November
1, 2017).
25. Hart LG, Larson EH, Lishner DM. Rural definitions for health
policy and research. Am J Public Health. (2005) 95:1149–55.
doi: 10.2105/AJPH.2004.042432
26. American Cancer Society. Colorectal Cancer Facts & Figures 2017–2017.
Atlanta, GA: American Cancer Society (2017).
27. Cokkinides VE, Chao A, Smith RA, Vernon SW, Thun MJ. Correlates of
underutilization of colorectal cancer screening among U.S. adults, age 50 years
and older. Prev Med. (2003) 36:85–91. doi: 10.1006/pmed.2002.1127
28. Ioannou GN, Chapko MK, Dominitz JA. Predictors of colorectal cancer
screening participation in the United States. Am J Gastroenterol. (2003)
98:2082–91. doi: 10.1111/j.1572-0241.2003.07574.x
29. Sirovich BE, Schwartz LM, Woloshin S. Screening men for prostate and
colorectal cancer in the United States: does practice reflect the evidence?
JAMA. (2003) 289:1414–20. doi: 10.1001/jama.289.11.1414
30. Tessaro I, Mangone C, Parkar I, Pawar V. Knowledge, barriers, and predictors
of colorectal cancer screening in an Appalachian church population. Prev
Chronic Dis. (2006) 3:A123.
31. Alyabsi M, Charlton M, Meza J, Islam KMM, Soliman A, WatanabeGalloway S. The impact of travel time on colorectal cancer stage at diagnosis
in a privately insured population. BMC Health Serv Res. (2019) 19:172.
doi: 10.1186/s12913-019-4004-6
32. Profile C. Blue Cross Blue Shield of Nebraska, Company Profile. (2017).
Available online at: https://www.nebraskablue.com/about/company-profile/
history (accessed July 7, 2017).
33. Gupta S, Tong L, Allison JE, Carter E, Koch M, Rockey DC, et al. Screening
for colorectal cancer in a safety-net health care system: access to care is critical
and has implications for screening policy. Cancer Epidemiol Biomarkers Prev.
(2009) 18:2373–9. doi: 10.1158/1055-9965.EPI-09-0344
34. Quan H, Parsons GA, Ghali WA. Validity of information on comorbidity
derived rom ICD-9-CCM administrative data. Med Care. (2002) 40:675–85.
doi: 10.1097/00005650-200208000-00007
35. Xue X, Agalliu I, Kim MY, Wang T, Lin J, Ghavamian R, et al. New methods for
estimating follow-up rates in cohort studies. BMC Med Res Methodol. (2017)
17:155. doi: 10.1186/s12874-017-0436-z

Frontiers in Public Health | www.frontiersin.org

9

November 2020 | Volume 8 | Article 532950

Alyabsi et al.

Colorectal Cancer Screening

64. Sauer AG, Liu B, Siegel RL, Jemal A, Fedewa SA. Comparing cancer
screening estimates: behavioral risk factor surveillance system and
national health interview survey. Prev Med. (2018) 106:94–100.
doi: 10.1016/j.ypmed.2017.10.019
65. Joseph DA, King JB, Richards TB, Thomas CC, Richardson LC. Peer reviewed:
use of colorectal cancer screening tests by state. Prev Chronic Dis. (2018)
15:E80. doi: 10.5888/pcd15.170535
66. Davis MM, Renfro S, Pham R, Lich KH, Shannon J, Coronado GD, et al.
Geographic and population-level disparities in colorectal cancer testing: a
multilevel analysis of medicaid and commercial claims data. Prev Med. (2017)
101:44–52. doi: 10.1016/j.ypmed.2017.05.001
67. Richman I, Asch SM, Bhattacharya J, Owens DK. Colorectal cancer screening
in the era of the affordable care act. J Gen Intern Med. (2016) 31:315–20.
doi: 10.1007/s11606-015-3504-2
68. United States Census Bureau. QuickFacts Nebraska. United States Census
Bureau (2017).
69. Singer BH, Ryff CD, Council NR. The Influence of Inequality on Health
Outcomes. Washington, DC: National Academies Press (2001).

56. Fenton JJ, Reid RJ, Baldwin LM, Elmore JG, Buist DS, Franks P.
Influence of primary care use on population delivery of colorectal
cancer screening. Cancer Epidemiol Biomarkers Prev. (2009) 18:640–5.
doi: 10.1158/1055-9965.EPI-08-0765
57. Zimmerman RK, Nowalk MP, Tabbarah M, Grufferman S. Predictors of
colorectal cancer screening in diverse primary care practices. BMC Health Serv
Res. (2006) 6:116. doi: 10.1186/1472-6963-6-116
58. Shires DA, Divine G, Schum M, Gunter MJ, Baumer DL, Kasprzyk D, et al.
Colorectal cancer screening use among insured primary care patients. Am J
Manag Care. (2011) 17:480–8.
59. Ferrante JM, McCarthy EP, Gonzalez EC, Lee JH, Chen R, LoveJackson K, et al. Primary care utilization and colorectal cancer outcomes
among Medicare beneficiaries. Arch Intern Med. (2011) 171:1747–57.
doi: 10.1001/archinternmed.2011.470
60. Dolan NC, Ramirez-Zohfeld V, Rademaker AW, Ferreira MR, Galanter WL,
Radosta J, et al. The effectiveness of a physician-only and physician-patient
intervention on colorectal cancer screening discussions between providers
and African American and Latino patients. J Gen Intern Med. (2015) 30:1780–
7. doi: 10.1007/s11606-015-3381-8
61. Laiyemo AO, Adebogun AO, Doubeni CA, Ricks-Santi L, McDonaldPinkett S, Young PE, et al. Influence of provider discussion and specific
recommendation on colorectal cancer screening uptake among U.S. adults.
Prev Med. (2014) 67:1–5. doi: 10.1016/j.ypmed.2014.06.022
62. Mosen DM, Feldstein AC, Perrin NA, Rosales AG, Smith DH, Liles EG, et al.
More comprehensive discussion of CRC screening associated with higher
screening. Am J Manag Care. (2013) 19:265–71.
63. Fan L, Mohile S, Zhang N, Fiscella K, Noyes K. Self-reported cancer
screening among elderly medicare beneficiaries: a rural-urban comparison.
J Rural Health. (2012) 28:312–9. doi: 10.1111/j.1748-0361.2012.
00405.x

Frontiers in Public Health | www.frontiersin.org

Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Alyabsi, Meza, Islam, Soliman and Watanabe-Galloway. This
is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) and the copyright owner(s) are credited
and that the original publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.

10

November 2020 | Volume 8 | Article 532950

